HotSpot Therapeutics
HotSpot Therapeutics is a biotechnology company focused on developing allosteric medicines for cancer and autoimmune diseases, utilizing its proprietary Smart Allostery™ platform.
Overview of HotSpot Therapeutics
HotSpot Therapeutics is pioneering a new class of allosteric medicines by targeting natural hotspots on proteins. This approach enables the development of differentiated medicines for patients, focusing on innovative treatment options for cancer and autoimmune diseases.
Innovative Allosteric Drug Development with Smart Allostery™
HotSpot Therapeutics utilizes a proprietary platform called Smart Allostery™. This platform integrates structure-function analysis, pharmacology, chemistry, and artificial intelligence to identify and target natural hotspots on proteins. The goal is to uncover and develop novel allosteric medicines, which represent a new frontier in drug discovery and treatment.
Recent Preclinical Data Presentations
HotSpot Therapeutics has recently presented preclinical data highlighting its innovative research. This includes a potential first-in-class MALT1 scaffolding inhibitor presented at the 65th ASH Annual Meeting. Additionally, the company showcased preclinical data from its CBL-B program at the 2023 Society for Immunotherapy of Cancer Annual Meeting, underscoring the company's ongoing commitment to advancing its drug discovery pipeline.
Funding and Financial Backing
HotSpot Therapeutics has successfully raised significant funding to support its mission. The company secured $100 million in Series C funding to advance its allosteric drug discovery platform. Additionally, it completed a $65 million Series B financing round aimed at progressing its pipeline of novel allosteric medicines. This financial backing reflects strong investor confidence in HotSpot Therapeutics’ innovative approach.
Strategic Acquisition of Macroceutics, Inc.
In a strategic move to enhance its drug discovery capabilities, HotSpot Therapeutics acquired Macroceutics, Inc., a provider of DNA-encoded library screening technologies. This acquisition aims to bolster HotSpot's ability to discover new drug candidates by leveraging Macroceutics' advanced screening technologies.